Abstract 3417: Peripheral CD8+CD28-suppressive T lymphocytes act as a prognosticator among breast cancer patients with adoptive T-cell immunotherapy
Song, Q; Ren, J; Yu, J; Wang, X; Zhou, X; Lyerly, HK
Published in: Cancer Research
Introduction: This study aimed to assess the prognostic value of CD8+CD28− T lymphocyte in peripheral blood among breast cancer patients treated with adoptive T lymphocytes immunotherapy.Methods: 217 patients participated in the follow-up study. CD8+CD28− proportion was measured by flow cytometry in peripheral T cells. The median survival was estimated by Kaplan-Meier curve, Log-rank test and Cox hazard proportion regression model, between groups of CD8+CD28− proportion more than 24.2% and less than or equal to 24.2% in peripheral T cells.ResultsThe median follow-up period was 15 months. Median time to progression was 11.8 months among patients with CD8+CD28− proportion less than or equal to 24.2% and 7.1 months among patients with CD8+CD28− proportion more than 24.2% (p<0.05). With further adjustments, CD8+CD28− proportion of more than 24.2% produced a HR being 2.13 (95%CI 1.45, 3.12) for progression. Patients with CD8+CD28− proportion of less than or equal to 24.2% had median overall survival of 36.2 months, 10.6-month longer than patients with higher CD8+CD28− proportion (p<0.05). With further adjustments, CD8+CD28− proportion of more than 24.2% produced a 86% higher risk for death (HR = 1.86, 95%CI 1.07, 3.24).ConclusionPeripheral CD8+CD28− proportion had a negative association with progression-free and overall survival among breast cancer patients receiving adoptive T cell immunotherapy. CD8+CD28− suppressive T cell was a potential biomarker for breast cancer patients’ prognosis.Citation Format: Qingkun Song, Jun Ren, Jing Yu, Xiaoli Wang, Xinna Zhou, Herbert Kim Lyerly. Peripheral CD8+CD28-suppressive T lymphocytes act as a prognosticator among breast cancer patients with adoptive T-cell immunotherapy. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3417.
